The United Kingdom and the United States have secured a key bilateral deal that will preserve zero levies on UK medicine shipments entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these vital exports will remain at zero for a period of three years.
This deal comes after previous warnings to dramatically increase tariffs on patented pharmaceutical imports, with figures mentioned up to one hundred percent.
"This deal between the United Kingdom strengthens the global environment for new treatments and establishes long-overdue equity to transatlantic medicine commerce," a statement said.
Trade Significance
Pharmaceuticals are one of the UK's biggest exports to the US, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to the third quarter, the UK exported medicines totaling £11.1bn to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This deal protects employment, stimulates capital expenditure and facilitates the UK to become a worldwide center for medical research," a minister remarked.
Specific British Pledges
The deal includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments were more than 20%.
Broader Context
The pact follows a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were heightened by assertions that American customers were paying several times more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
